Summary

Eligibility
for people ages 18-90 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Keywords

Transthyretin Amyloid Cardiomyopathy, Amyloid Depleter, ALXN2220, All-cause mortality (ACM), Cardiovascular (CV), Transthyretin amyloid (ATTR), Transthyretin (TTR), N-terminal pro b-type natriuretic peptide (NT-proBNP), NT-proBNP, Amyloidosis, ATTR-CM, Cardiomyopathies

Eligibility

Locations

  • Research Site
    San Francisco California 94143 United States
  • Research Site
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Alexion Pharmaceuticals, Inc.
ID
NCT06183931
Phase
Phase 3 Cardiomyopathy Research Study
Study Type
Interventional
Participants
About 1158 people participating
Last Updated